SGS Opens New Facility in Germany
News Sep 09, 2016
SGS has announced that it has opened a new facility in Wiesbaden, Germany, exclusively to offer extractables and leachables testing for the pharmaceutical and related industries. SGS previously offered these services from its Taunusstein, Germany laboratory, approximately 20 kilometers from the new site, but customer demand has seen the need for a dedicated facility and increased investment in this business. The 500 sq. m. facility accommodates an increased number of scientists.
Equipment and instruments that have been both transferred from Taunusstein, and newly acquired, have been qualified and validated in the new laboratory. Ongoing projects being undertaken for clients have been successfully transferred to Wiesbaden, and the space vacated at Taunusstein creates an opportunity for SGS to expand its quality control release testing capabilities at that facility.
“This investment, in both a new facility and advanced analytical technologies is in response to increased awareness of regulatory requirements globally and growing customer demand,” commented Dr. Sheida Hoenlinger, Director, Life Sciences Germany. “SGS has a very strong reputation within the industry for extractables and leachables testing, and this step, to build a dedicated facility, allows us to offer our clients greater opportunities to identify the unknowns through more sensitive and accurate impurity profiling techniques.”
The new facility in Wiesbaden will be SGS’s global Center of Excellence for Extractable Studies and Impurities Profiling, as a hub across the global network of laboratories. With 21 laboratories offering contract analytical and bioanalytical services, SGS leverages its wholly-owned global network, present in North America, Europe, and Asia, to deliver harmonized solutions to large pharmaceutical and biotechnology firms.
In addition to testing services for the bio/pharmaceutical market, SGS also provides Phase I-IV clinical trial management, and services encompassing data management and statistics, PK/PD modeling and simulation, pharmacovigilance and regulatory consultancy.
The Alzheimer drug candidate PRI-002 has successfully completed Phase I of clinical research involving healthy volunteers. When administered daily over a period of four weeks, the active substance proved to be safe for use in humans. The next milestone will be the proof of efficacy in patients in clinical Phase II.READ MORE